Oncotelic Hopes to Leverage Intranasal Apomorphine to Treat Parkinson’s Disease

Oncotelic Inc., an immuno-oncology company developing RNA therapeutics and small molecule drugs to treat cancers and infectious diseases, is branching out. On Monday, the company announced that it had licensed an intranasal apomorphine asset from Autotelic Inc. for the treatment of Parkinson’s disease (PD), Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD).